Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) was the recipient of a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 7,739,760 shares, a decline of 31.0% from the February 15th total of 11,218,968 shares. Approximately 15.7% of the shares of the company are short sold. Based on an average daily trading volume, of 1,411,124 shares, the days-to-cover ratio is currently 5.5 days.
NYSEAMERICAN AMPE traded up $0.13 on Monday, hitting $3.40. 1,030,300 shares of the company were exchanged, compared to its average volume of 1,191,543. Ampio Pharmaceuticals has a 1-year low of $0.38 and a 1-year high of $4.95.
A number of institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN increased its stake in shares of Ampio Pharmaceuticals by 113.7% in the 4th quarter. Wells Fargo & Company MN now owns 40,671 shares of the specialty pharmaceutical company’s stock valued at $166,000 after acquiring an additional 21,638 shares during the last quarter. LPL Financial LLC bought a new stake in shares of Ampio Pharmaceuticals in the 4th quarter valued at about $115,000. Creative Planning bought a new stake in shares of Ampio Pharmaceuticals in the 4th quarter valued at about $116,000. Raymond James & Associates bought a new stake in shares of Ampio Pharmaceuticals in the 4th quarter valued at about $137,000. Finally, Cypress Capital Management LLC WY increased its stake in shares of Ampio Pharmaceuticals by 50.6% in the 4th quarter. Cypress Capital Management LLC WY now owns 108,400 shares of the specialty pharmaceutical company’s stock valued at $441,000 after acquiring an additional 36,400 shares during the last quarter.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Enterprise Leader and is owned by of Enterprise Leader. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://theenterpriseleader.com/2018/04/02/ampio-pharmaceuticals-inc-nyseamericanampe-sees-significant-decrease-in-short-interest.html.
Ampio Pharmaceuticals Company Profile
Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.